Exploring Cannabis for Chronic Low Back Pain Management
Chronic low back pain (CLBP) affects over half a billion people globally, significantly impacting quality of life and productivity. Current pharmacological treatments, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids, often offer limited long-term efficacy and carry substantial risks, including severe side effects and the potential for dependence. This pressing need for safer and more effective alternatives has led to growing scientific interest in the potential of cannabis-based medicines. A recent multicenter, randomized, placebo-controlled phase 3 trial, published in Nature Medicine, investigated the efficacy and safety of VER-01, a full-spectrum cannabis extract, for individuals living with CLBP, offering new insights into cannabis for chronic low back pain.
Understanding the Research: A Phase 3 Trial
The study enrolled 820 adults with CLBP, with participants randomly assigned to receive either VER-01 (n=394) or a placebo (n=426). A key strength of this research was its use of a chemically well-defined, full-spectrum cannabis extract, VER-01, which underwent comprehensive characterisation to ensure batch-to-batch consistency. This approach addresses previous limitations in cannabis research, where variability in product composition has often made findings difficult to reproduce or compare.
- Phase A: A 12-week double-blind treatment period, focusing on changes in mean Numeric Rating Scale (NRS) pain intensity as the primary endpoint. For participants with a neuropathic pain component, changes in the total Neuropathic Pain Symptom Inventory (NPSI) score served as a key secondary endpoint.
- Phase B: A 6-month open-label extension, allowing all participants to receive VER-01.
- Phase C: A 6-month continuation phase for some participants.
- Phase D: A randomized withdrawal phase, designed to assess the time to treatment failure.
Study Outcomes for Pain Management
The study met its primary endpoint in Phase A, demonstrating a statistically significant reduction in pain intensity for the VER-01 group. Participants receiving VER-01 experienced a mean pain reduction of −1.9 NRS points from baseline, compared to −1.4 points in the placebo group, resulting in a mean difference of −0.6 points (95% CI = −0.9 to −0.3; P < 0.001). This difference was consistently observed across all 12 weeks of the treatment phase.
For individuals with a neuropathic pain component, the study also met its key secondary endpoint. The VER-01 arm showed a mean NPSI decrease of −14.4 points from baseline, significantly greater than the −7.2 points observed in the placebo arm (mean difference = −7.3; P = 0.017). These improvements extended beyond pain scores, with VER-01 associated with:
- Significant improvements in sleep quality.
- Enhanced physical function.
- Elevated quality of life, as measured by the SF-36 physical health component summary score.
- A higher rate of participants reporting overall improvement on the patient global impression of change scale.
- Reduced use of rescue medication compared to the placebo group.
These findings suggest that VER-01 may offer a comprehensive benefit for individuals managing CLBP, addressing multiple aspects of their condition.
Safety Profile and Sustained Effects
Regarding safety, the incidence of adverse events was higher in the VER-01 group (83.3%) compared to placebo (67.3%) during Phase A (P < 0.001). However, most reported adverse events were mild to moderate and transient. Importantly, the study reported that VER-01 was well-tolerated, with no signs of dependence or withdrawal symptoms observed, which is a critical consideration given the concerns surrounding opioid use in chronic pain management.
The benefits observed in Phase A appeared to be sustained and even deepened in subsequent phases. During the 6-month open-label Phase B, participants experienced further reductions in NRS pain intensity, with effects maintained through Phase C. There were no indications of diminishing efficacy or the need for dose escalation over time. While Phase D, the randomized withdrawal phase, did not meet its primary endpoint of time to treatment failure, it did indicate that pain increased significantly more in the placebo group upon withdrawal, suggesting a continued therapeutic effect from VER-01.
This research contributes valuable evidence to the discussion around cannabis for chronic low back pain, highlighting the potential of a well-characterised cannabis extract as a viable option for patients seeking alternatives to conventional treatments.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
